You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The device will be used with MDxHealth's SelectMDx for Prostate Cancer IVD kit, which will launch later this year.
Lab21 will serve as a non-exclusive distributor of the SelectMDx prostate cancer test in the UK.
The company said the revenue increase was driven by strong growth in its ConfirmMDx prostate cancer test and the launch of its SelectMDx liquid biopsy test.
The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.
ConfirmMDx is an epigenetic tissue-based test for the early detection of prostate cancer, specifically aimed at addressing false-negative biopsy concerns.
The deal marks the latest in a series of distribution agreements MDxHealth has recently signed for the SelectMDx test.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The insurer operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas, and will now cover ConfirmMDx for its customers.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
Biotechnology company SouthGenetics will distribute the prostate cancer test in countries including Argentina, Chile, Mexico, Peru, Panama, and Venezuela.